Vera Therapeutics to report results from ORIGIN Phase 2b clinical trial

Vera Therapeutics announced that long-term results from the ORIGIN Phase 2b clinical trial of atacicept for the treatment of IgAN will be delivered in a late-breaking oral presentation, and two informational posters will describe the ORIGIN Phase 3 and ORIGIN Extend trials, at the American Society of Nephrology, or ASN, Kidney Week 2024 in San Diego, California, from October 23 to 27. “Long-term Results from the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgAN” will be presented by Jonathan Barratt, The Mayer Professor of Renal Medicine, University of Leicester. “ORIGIN 3: A Global Randomized, Controlled, Phase 3 Study of Atacicept in IgAN” will be presented by Richard Lafayette, Professor of Medicine, Nephrology and Director of the Stanford Glomerular Disease Center at Stanford University Medical Center. “ORIGIN Extend: A Long-Term Extension Study of Atacicept in IgAN” will presented by Richard Lafayette, Professor of Medicine, Nephrology and Director of the Stanford Glomerular Disease Center at Stanford University Medical Center.